Five-year survival in luminal breast cancer patients: relation with intratumoral activity of proteasomes

被引:2
|
作者
Sereda, Elena E. [1 ,2 ]
Kolegova, Elena. S. [3 ]
Kakurina, Gelena V. [1 ,2 ]
Korshunov, Dmitriy A. [1 ]
Sidenko, Evgenia A. [1 ]
Doroshenko, Artem V. [4 ]
Slonimskaya, Elena M. [4 ]
Kondakova, Irina V. [1 ]
机构
[1] Russian Acad Sci, Canc Res Inst, Tomsk Natl Res Med Ctr, Lab Tumor Biochem, Tomsk 634009, Russia
[2] Siberian State Med Univ, Fac Med & Biol, Dept Biochem & Mol Biol, Tomsk 634050, Russia
[3] Russian Acad Sci, Canc Res Inst, Tomsk Natl Res Med Ctr, Lab Canc Progress Biol, Tomsk, Russia
[4] Russian Acad Sci, Canc Res Inst, Dept Gen Oncol, Tomsk Natl Res Med Ctr, Tomsk, Russia
来源
关键词
Luminal breast cancer; hematogenous metastases; proteasomes activity; long-term outcome; prognosis; ESTROGEN-RECEPTOR-ALPHA; KAPPA-B; TARGET; PHOSPHORYLATION; UBIQUITYLATION; DEGRADATION; PROTEIN;
D O I
10.21037/tbcr-22-22
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The purpose of the study was to analyze the relationship between the caspase-like (CL) and chymotrypsin-like (ChTL) activities of proteasomes and the 5-year overall and metastasis-free survival rates in patients with luminal breast cancer. Methods: The study included 117 patients with primary operable invasive breast cancer (T1-2N0-1M0). Tissue samples from breast cancer patients were obtained as a result of the radical mastectomy or breast conserving surgery, which was a first line of therapy. The ChTL and CL proteasomes activities in the tumor tissue and in the surrounding adjacent breast tissues were assessed using the fluorometric method. The coefficients of ChTL (cChTL) and CL (cCL) proteasomes activities were also determined. The coefficients were calculated as the ratio of the corresponding proteasomes activity in the tumor tissue to the surrounding adjacent breast tissues. Within 5 years of follow-up, hematogenous metastases occurred in 14% of patients with luminal A breast cancer, in 31% of patients with luminal B human epidermal growth factor receptor-2 (HER-2) negative and in 23% of patients with luminal B HER-2 positive breast cancers. The study protocol was approved by the Local Ethics Committee of the Cancer Research Institute of Tomsk National Research Medical Center. Written informed consent was obtained from all patients. Results: An increase in the ChTL and CL proteasomes activities was shown in all studied molecular subtypes of breast cancer compared to adjacent tissues. It was found that the cChTL of >35.9 U/mg protein and the cCL of >2.21 in breast cancer patients were associated with the development of distant metastases. In patients with luminal A breast cancer, the 5-year metastasis-free survival rates were associated only with the value of cCL of proteasomes (log-rank test: P=0.008). In patients with luminal B HER-2 negative breast cancer, the 5-year metastasis-free survival rates were associated with the levels of ChTL and cCL proteasomes activities (log-rank test: P=0.02 and P=0.04, respectively). Conclusions: The data obtained on the correlation of 5-year metastasis-free survival rates with the level of proteasomes activities indicate the possibility of their use as additional prognostic criteria for breast cancer.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Radiation therapy: A major factor in the five-year survival analysis of women with breast cancer in Lagos, Nigeria
    Makanjuola, Samira B. L.
    Popoola, Abiodun O.
    Oludara, Mobolaji A.
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 (02) : 321 - 326
  • [42] Estimating the Five-Year Survival of Cervical Cancer Patients Treated in Hospital Universiti Sains Malaysia
    Abd Razak, Nuradhiathy
    Khattak, M. N.
    Zubairi, Yong Zulina
    Naing, Nyi Nyi
    Zaki, Nik Mohamed
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (02) : 825 - 828
  • [43] NEOADJUVANT CHEMOIMMUNOTHERAPY INCREASES THE OVERALL FIVE-YEAR SURVIVAL OF PATIENTS WITH LOCALLY ADVANCED CERVICAL CANCER
    Menshenina, A.
    Moiseenko, T.
    Frantsiyants, E.
    Verenikina, E.
    Ushakova, N.
    Adamyan, M.
    Chalabova, T.
    Selezneva, G.
    Maksimova, N.
    Pustovalova, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A70 - A70
  • [44] Five-year Survival and Prognostic Factors in a Cohort of Breast Cancer Patients Treated in Brazilian National Cancer Institute, Rio De Janeiro, Brazil
    Bello, M.
    Millen, E. C.
    Carmo, P. A. O.
    Motta, R. C.
    Thuler, L. C. S.
    Bergmann, A.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S87 - S88
  • [45] Five-year overall survival of patients with advanced bladder cancer in Kazakhstan: OSURK registry study
    Shatkovskaya, Oxana
    Kaidarova, Dilyara
    Ongarbayev, Bakytzhan
    Sagi, Madina
    Tsimafeyeu, Ilya
    AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY, 2023, 11 (06): : 542 - 548
  • [46] Use of Period Analysis to Timely Assess Five-Year Relative Survival for the Patients With Bone Cancer
    Xie, Xian Kuan
    Zhao, Xiao Jiao
    Li, Run Hua
    Cheng, Yong Ran
    Bing, Xin
    Yang, Jun
    Wang, Liang You
    Zhu, Hui Jun
    Chen, Tian Hui
    Chen, Jin Fei
    WORLD JOURNAL OF ONCOLOGY, 2024, 15 (04) : 675 - 681
  • [48] Five-year actual survival after pancreatoduodenectomy for pancreatic head cancer
    Perysinakis, Iraklis
    Avlonitis, Spyridon
    Georgiadou, Despoina
    Tsipras, Hercules
    Margaris, Ilias
    ANZ JOURNAL OF SURGERY, 2015, 85 (03) : 183 - 186
  • [49] Five-year Relative Survival Rate of Cancer in the USA, Europe and Japan
    Saika, Kumiko
    Machii, Ryoko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (10) : 1053 - 1054